GSK (LON:GSK) Insider Jonathan Symonds Purchases 1,650 Shares

GSK plc (LON:GSK) insider Jonathan Symonds acquired 1,650 shares of the stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of GBX 1,810 per share, with a total value of £29,865.

GSK Stock Performance

GSK stock traded up GBX 9.75 during midday trading on Monday, reaching GBX 1,810. The stock had a trading volume of 2,065,858,250 shares, compared to its average volume of 19,663,850. The firm has a fifty day simple moving average of GBX 1,758.28 and a two-hundred day simple moving average of GBX 1,565.36. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,853.50. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market cap of £73.08 billion, a PE ratio of 13.61, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GSK shares. Berenberg Bank upped their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Shore Capital reissued a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research note on Monday, October 20th. JPMorgan Chase & Co. upped their price target on shares of GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a research report on Friday, November 7th. Finally, Jefferies Financial Group lifted their price objective on GSK from GBX 2,000 to GBX 2,100 and gave the stock a “buy” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,762.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.